Press release from Companies
Publicerat: 2022-06-24 18:15:51
COPENHAGEN – Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS). The Company’s managerial employee have given Curasight power of attorney on her behalf to publish purchase of Curasight shares as managerial employee conducted in the period 9 – 10 June 2022.
The transaction comprises the following managerial employee; Hanne Damgaard Jensen total holdings in Curasight A/S after the purchase of the shares is 20,000 shares. For further information regarding Curasight, please contact: Ulrich Krasilnikoff, CEO Phone: +45 22 83 01 60 E-mail: uk@curasight.com Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.
Name
Position
Aggregated volume
Price, DKK
Hanne Damgaard Jensen
Chief Development Officer
16.400
227,218.81
Total
16,400
227,218.81